- ►diabetesjournals.org A Gastaldelli, Y Miyazaki, A Mahankali, R … - Diabetes Care, 2006 - Am Diabetes Assoc RESULTS—Fasting plasma glucose (FPG) (10.0 ± 0.8 to 7.7 ± 0.7 mmol/l) and
HbA 1c (9.0 ± 0.4 to 7.3 ± 0.6%) decreased in the PIO and increased in Plc
group (P < 0.05 PIO vs. Plc). Insulin sensitivity increased ∼40% during ... Cited by 23 - Related articles - BL Direct - All 5 versions
R Basu, P Shah, A Basu, B Norby, B Dicke, … - Diabetes, 2008 - Am Diabetes Assoc RESULTS—Glucose was clamped before and after therapy at ∼5 mmol/l, insulin
raised to ∼180 pmol/l, C-peptide suppressed with somatostatin, glucagon
replaced at ∼75 pg/ml, and glycerol maintained at ∼200 mmol/l to ensure ... Cited by 10 - Related articles - BL Direct - All 8 versions
K Osei, T Gaillard, D Schuster - Metabolism, 2007 - Elsevier Peripheral insulin levels are determined by beta-cell secretion, insulin
sensitivity, and hepatic insulin extraction (HIE). We have previously shown that
whereas sulfonylureas reduce insulin extraction, metformin enhances HIE. ... Cited by 8 - Related articles - All 14 versions
A Gastaldelli, A Casolaro, M Pettiti, M … - Clinical Pharmacology & Therapeutics, 2007 - nature.com We explored the mechanisms by which a 4-month, placebo-controlled pioglitazone
treatment (45 mg/day) improves glycemic control in type II diabetic patients
(T2D, n=27) using physiological testing (6-h mixed meal) and a triple ... Cited by 8 - Related articles - All 4 versions
R Jain, K Osei, S Kupfer, AT Perez, J Zhang - Pharmacotherapy, 2006 - PPI Rajeev Jain, MD, Kwame Osei, MD, Stuart Kupfer, MD, Alfonso T. Perez, MD, and
Jeff Zhang, MS ... Study Objective. To evaluate the long-term safety and
efficacy of glyburide versus pioglitazone in patients with a recent ... Cited by 10 - Related articles - BL Direct - All 9 versions
G Perriello, S Pampanelli, C Pietro, P Brunetti - Diabetic Medicine, 2006 - interscience.wiley.com Methods This was a double-blind, multicentre, comparative, parallel group trial
in 283 patients with Type 2 diabetes, who were randomized to receive 1-year
treatment with pioglitazone 30–45 mg/day or gliclazide 80–320 mg/day. ... Cited by 10 - Related articles - BL Direct - All 4 versions
PK Sharma, A Bhansali, R Sialy, S Malhotra, … - CLINICAL ENDOCRINOLOGY-OXFORD-, 2006 - medscape.com Adipose tissue is now recognized as an endocrine organ, which secretes several
mediators with diverse functions collectively known as adipocytokines. [1] One
such adipocytokine, adiponectin has been identified [2,3] and accounts for ... Cited by 11 - Related articles - BL Direct - All 8 versions
- ►physiology.org A Gastaldelli, E Ferrannini, Y Miyazaki, M … - American Journal of Physiology- Endocrinology And …, 2007 - Am Physiological Soc Thiazolidinediones (TZDs) improve glycemic control and insulin sensitivity in
patients with type 2 diabetes mellitus (T2DM). There is growing evidence from in
vivo and in vitro studies that TZDs improve pancreatic -cell function. The ... Cited by 39 - Related articles - BL Direct - All 6 versions
Y Nishimura, Y Inoue, H Takeuchi, Y Oka - Acta Diabetologica, 1997 - Springer Abstract Pioglitazone, a thiazolidinedone derivative, de- creases insulin
resistance and improves hyperglycemia in in- sulin-resistant obese and/or
diabetic animals. However, the mechanisms by which hyperglycemia is ... Cited by 13 - Related articles - BL Direct - All 3 versions
